OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference



    VANCOUVER, June 9 /CNW/ - OncoGenex Technologies Inc. will present at the
Needham & Company 7th Annual Biotechnology & Medical Technology Conference on
June 11 at 3 p.m. ET at the New York Palace Hotel. OncoGenex' President and
Chief Executive Officer, Scott Cormack, will provide a corporate overview at
the conference, including an overview of the Company's most recent data
presentations from the American Society of Clinical Oncology (ASCO) 2008 and
the American Society of Clinical Oncology (ASCO) Genitourinary 2008 cancer
conferences.

    About OncoGenex

    OncoGenex is a private biopharmaceutical company committed to the
development and commercialization of new cancer therapies that address
treatment resistance in cancer patients. The company's three product
candidates are designed to inhibit the production of specific proteins
associated with treatment resistance and which are over-produced in response
to a variety of cancer treatments. OGX-011 is completing evaluation in five
Phase 2 clinical studies in prostate, lung, and breast cancers. OGX-427 has
begun evaluation in Phase 1 clinical studies, while the third product
candidate, OGX-225, has completed preclinical pharmacology studies. More
information is available at www.oncogenex.ca.

    Definitive Agreement to Merge

    On May 28, 2008, Sonus Pharmaceuticals, Inc. (NASDAQ:   SNUS) and OncoGenex
Technologies Inc., jointly announced the signing of a definitive agreement to
merge the two companies. The proposed transaction is subject to the approval
of Sonus' and OncoGenex' shareholders and in the case of OncoGenex, court
approval under the arrangement provisions of the Canada Business Corporations
Act.

    Safe Harbor

    This press release contains forward-looking statements, including
statements concerning clinical trial results and the proposed merger between
Sonus and OncoGenex. These statements are based on management's current
expectations and beliefs and are subject to a number of risks, uncertainties
and assumptions that could cause actual results to differ materially from
those described in the forward-looking statements. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. For example, statements regarding the timing and
anticipated results of clinical trials and development efforts and the timing
of closing the proposed merger are all forward-looking statements. The
potential risks and uncertainties include, among others, that clinical results
will not be maintained in final data analysis, that current or future clinical
trials will not be successful or confirm the results of earlier studies, risks
related to the timing and costs of clinical trials and regulatory approvals,
risks associated with obtaining funding from third parties or completing a
financing necessary to support the costs and expenses of clinical studies,
risks relating to the development, safety and efficacy of therapeutic drugs
and potential applications for these products and the possibility that the
merger with Sonus does not close or that the closing may be delayed. No
assurances can be given that any of the events anticipated by the
forward-looking statements will transpire or occur, or if any of them do so,
what impact they will have on the results of operations or financial condition
of OncoGenex. The Company undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof.





For further information:

For further information: OncoGenex Media and Investor Contact: Jason I.
Spark, Porter Novelli Life Sciences, (619) 849-6005,
jspark@pnlifesciences.com

Organization Profile

ONCOGENEX TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890